Taylor declares that he has been involved in speakers' bureaux (honoraria) and acted as a consultant for UCB, Bristol-Myers Squibb, Roche, Centocor JNJ, Schering-Plough, Wyeth and Abbott
However, further prospective cohort studies with clinical endpoints in healthy subjects, and results from on-going randomized, placebo-controlled interventional trials are awaited to truly define the efficiency of homocysteine-lowering therapy in the prevention and correction of vascular disorders among patients with occlusive coronary artery, cerebrovascular and peripheral vascular diseases, and thrombosis related to hyperhomocysteinemia
however, these findings must be interpreted with caution, because these studies included patients with normal LVEF
[DOI] [PubMed] [Google Scholar] 60.Kalista S, Schakman O, Gilson H, et al